Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3582]

Researchers discover why one type of chemotherapy works best in bladder cancer

Researchers discover why one type of chemotherapy works best in bladder cancer

FDG PET/CT imaging after just one week may predict treatment response in patients with advanced melanoma

FDG PET/CT imaging after just one week may predict treatment response in patients with advanced melanoma

Analysis shows that secondary cancers following CAR T cell therapy are rare

Analysis shows that secondary cancers following CAR T cell therapy are rare

Why cancer immunotherapies don’t work for everyone

Why cancer immunotherapies don’t work for everyone

ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate cancer with poor prognosis

ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate...

ASCO GI 2024: Adding immunotherapy-based combination to TACE improves progression-free survival in patients with most common liver cancer

ASCO GI 2024: Adding immunotherapy-based combination to TACE improves progression-free survival in patients with...

ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer

ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer

ASCO GI 2024: Dual immunotherapy treatment improves progression-free survival in certain patients with advanced colorectal cancer

ASCO GI 2024: Dual immunotherapy treatment improves progression-free survival in certain patients with advanced...

New research tool seeks to accelerate hunt for cancer immunotherapy targets

New research tool seeks to accelerate hunt for cancer immunotherapy targets

Aberrant RBMX expression relevant for cancer prognosis and immunotherapy response

Aberrant RBMX expression relevant for cancer prognosis and immunotherapy response

More from ecancer